Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. VIII: CAR-T cells: preclinical development - Safety and efficacy evaluation

Currently, there are four CAR-T products commercially available on the market. CAR-T cells have shown high remission rates and they represent an effective treatment option for patients with resistant or refractory B cell malignancies. Approval of these cell therapy products came after an extended pe...

Descripción completa

Detalles Bibliográficos
Autores principales: Picanço-Castro, Virginia, Bonamino, Martín Hernan, Ramos, Rodrigo Nalio, Guerino-Cunha, Renato L., Oliveira, Theo Gremen M., Rego, Eduardo M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sociedade Brasileira de Hematologia e Hemoterapia 2021
Materias:
Special Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8606693/
https://www.ncbi.nlm.nih.gov/pubmed/34794798
http://dx.doi.org/10.1016/j.htct.2021.09.008
Descripción
Sumario:Currently, there are four CAR-T products commercially available on the market. CAR-T cells have shown high remission rates and they represent an effective treatment option for patients with resistant or refractory B cell malignancies. Approval of these cell therapy products came after an extended period of preclinical evaluation that demonstrated unprecedented efficacy in this difficult-to-treat patient population. This review article outlines the main preclinical evaluations needed for CAR T cell product development.

Ejemplares similares